Cross-institution positioning
Jan 29, 2026Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 researchACET Institutional Ownership
Adicet Bio, Inc.
Latest stored close $5.74 as of Oct 8, 2026 View live quote ↗
STOCKNODE Outlook
Neutral
60/100
1 tracked · 0 comparable
Latest filing
Jan 29, 2026
Positive breadth
1 positive · 0 negative
Recent close
$5.74
Research confidence
Limited
Institutional Research 55/100 · 0 accumulating · 0 reducing / exited
Ownership history
Reported ownership % history
Latest filing Jan 29, 2026
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
Locked preview
Unlock the reported ownership timeline
Unlock full research
Accumulating0
Newly reported1
Reducing / exited
0
52-week position
—
Institutional Intelligence
Why STOCKNODE says Neutral
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
STOCKNODE Outlook
Neutral 60/100
Confidence:Limited
Why this signal
- 0 tracked institutions accumulating versus 0 reducing/exited.
- Latest comparable Form 13F activity is net positive across tracked managers.
- Comparable SEC fundamentals are improving.
Institutional
61/100
Insiders
50/100
Fundamentals
70/100
Events
50/100
Quarterly 13F activity
Jun 30, 20261 increased/new, 0 reduced/exited, and 1 unchanged across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsInsider filing activity
Aug 5, 2026Recent Forms 3/4/5 activity is available, with no non-amendment non-derivative SEC-coded P/S transactions in the rolling 90-day window. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/5Material company events
Sep 28, 20264 non-amendment material events in the last 90 days; Latest classified evidence: Regulation FD disclosure. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataSEC fundamentals
Aug 5, 2026Net income +31.6% YoY; Free cash flow +22.4% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsPrice context
Sep 15, 2026Recent close is 22% through its reported 52-week range; -33.7% over one year.
Source: Stored historical price series
Latest filing decision brief
Investor / Pro
Research the latest Initial Schedule 13G from Franklin Resources.
Filed Jan 29, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
Supporting institutional evidence
Institutional Evidence
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Latest filing
Jan 29, 2026
Latest reported position changes
Investor / Pro detailSee each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Franklin Resources
Filed Jan 29, 2026
Direction locked
Unlock the actual direction, share change, ownership change, and classification basis.
No premium position values are sent in this locked preview.
Unlock full research
Reported direction breadth by as-of date
Locked previewComparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Unlock actual accumulation vs. reduction breadth across reported position dates.
View plans
Institution comparison
Investor / Pro detailCompare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Franklin Resources
Filed Jan 29, 2026
Unlock the evidence behind the score
Know who changed position, by how much, and when the SEC learned about it.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
✓ Actual share and ownership changes
✓ Position as-of date vs. SEC filed date
✓ Deterministic direction basis
✓ Full evidence on every eligible stock
SEC Forms 3, 4 & 5
Insider activity
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
30-day purchases00 reporting owner(s)
30-day sales00 reporting owner(s)
90-day purchase breadth0
90-day sale breadth0
View recent insider filing evidence
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | Klickstein Lloyd | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 18.3K | $0.00 | Direct | Aug 7, 2026 |
| Jun 21, 2026 | DUBIN STEVE | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 4.2K | $0.00 | Direct | Jun 23, 2026 |
| Jun 21, 2026 | Chodakewitz Jeffrey | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 4.2K | $0.00 | Direct | Jun 23, 2026 |
| Jun 21, 2026 | Grissinger Michael | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 4.2K | $0.00 | Direct | Jun 23, 2026 |
| Jun 21, 2026 | Sinclair Andrew | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 4.2K | $0.00 | Direct | Jun 23, 2026 |
| Jun 21, 2026 | Peng Katie | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 4.2K | $0.00 | Direct | Jun 23, 2026 |
| Jun 21, 2026 | Klickstein Lloyd | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 4.2K | $0.00 | Direct | Jun 23, 2026 |
| Jun 19, 2026 | Schor Chen | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 55.0K | $0.00 | Direct | Jun 23, 2026 |
| Jun 19, 2026 | Aftab Blake | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 55.0K | $0.00 | Direct | Jun 23, 2026 |
| Apr 27, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | JOther transaction · derivative | Pre-Funded Warrant (Right to Buy) | 250.0K | — | Indirect | Apr 29, 2026 |
| Apr 27, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | JOther transaction | Common Stock | 250.0K | — | Indirect | Apr 29, 2026 |
| Apr 8, 2026 | ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | SOpen-market or private sale | Common Stock | 40.4K | $6.52 | Indirect | Apr 9, 2026 |
| Apr 8, 2026 | ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | SOpen-market or private sale | Common Stock | 32.5K | $6.29 | Indirect | Apr 9, 2026 |
| Apr 7, 2026 | ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | SOpen-market or private sale | Common Stock | 2.4K | $6.38 | Indirect | Apr 9, 2026 |
| Apr 7, 2026 | ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | SOpen-market or private sale | Common Stock | 29.3K | $6.53 | Indirect | Apr 9, 2026 |
| Feb 20, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Common Stock | 74.8K | $7.27 | Indirect | Apr 13, 2026 |
| Feb 19, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Common Stock | 74.3K | $7.21 | Indirect | Apr 13, 2026 |
| Feb 18, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | POpen-market or private purchase | Common Stock | 74.6K | $7.04 | Indirect | Apr 13, 2026 |
SEC company-event context
Material company events
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
30-day material events3
90-day capital-related0
90-day equity-related0
90-day debt-related0
View recent company-event filing evidence
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Sep 28, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Sep 8, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Sep 1, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Aug 5, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jun 18, 2026 | 8-K | 5.07 | Shareholder vote results | — | Filing |
| May 13, 2026 | S-8 POS | — | Employee-plan securities registration | Equity | Filing |
| May 13, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Apr 28, 2026 | 8-K | 3.02, 9.01 | Unregistered sale of equity securities; Financial statements / exhibits | Equity | Filing |
| Mar 12, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Mar 12, 2026 | S-3 | — | Shelf securities registration | Capital-related | Filing |
| Mar 12, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jan 7, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
SEC-reported company fundamentals
Fundamentals
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Operating income
$-22.3M
Q2 2026
+31.2% YoY 10-Q filed Aug 5, 2026
Net income
$-21.4M
Q2 2026
+31.6% YoY 10-Q filed Aug 5, 2026
Diluted EPS
$-1.99
Q2 2026
+63.7% YoY 10-Q filed Aug 5, 2026
Operating cash flow
$-41.3M
YTD through Jun 30, 2026
+20.6% YoY 10-Q filed Aug 5, 2026
Free cash flow
$-41.6M
YTD through Jun 30, 2026
+22.4% YoY 10-Q filed Aug 5, 2026
Cash & equivalents
$33.1M
As of Jun 30, 2026
-4.6% YoY 10-Q filed Aug 5, 2026
Assets
$148.2M
As of Jun 30, 2026
-9.1% YoY 10-Q filed Aug 5, 2026
Liabilities
$28.0M
As of Jun 30, 2026
-5.3% YoY 10-Q filed Aug 5, 2026
Stockholders’ equity
$120.1M
As of Jun 30, 2026
-9.9% YoY 10-Q filed Aug 5, 2026
Shares outstanding
9.4M
As of Aug 3, 2026
-88.8% YoY 10-Q filed Aug 5, 2026
Current market context
Price performance
Dated price context from the historical market series already collected for this security.
Recent stored close
$8.51
View live quote ↗
52-week low
$6.01
Mar 30, 2026
52-week high
$17.44
Oct 13, 2025
Below 52-week high
51.2%
Split-adjusted 52-week range · 1 split in this window
Historical prices and the 52-week high/low are normalized to the current share basis so prices before and after a stock split remain directly comparable.
- Dec 30, 2025: 1-for-16 reverse split.
1W return
-12.6%
1M return
+1.5%
3M return
+4.9%
6M return
+18.0%
YTD return
+1.0%
1Y return
-33.7%
30-day volatility
67.7%
90-day volatility
67.6%
1Y max drawdown
-63.3%
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.
Beneficial ownership filing history
Showing 2 of 2 filing(s)View beneficial ownership filing evidence
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Franklin Resources CIK0000038777 | Dec 31, 2025 quarter end Feb 11, 2026 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 626.6K | $5.74 | |||
| Franklin Resources CIK0000038777 | Dec 31, 2025 observed Jan 29, 2026 filed · 29d Initial Schedule 13G | Initial Schedule 13G | 626.6K | 6.50% | $8.42 | $8.50 | $5.74 |
Explore more institutional activity
Related research
Compare ACET with other securities showing similar institutional activity or recent accumulation across several tracked institutions.